BioTuesdays

Category - Markets

89bio
Markets

SVB Leerink starts 89bio at OP; PT $55

SVC Leerink initiated coverage of 89bio (NASDAQ:ETNB) with an “outperform” rating and $55 price target. The stock closed at $28.60 on Dec. 6. 89bio is developing a fibroblast growth factor (FGF) 21 analog, BIO89-100, in...

December 9, 2019
Diplomat Pharmacy
Markets

WB ups Diplomat Pharmacy to market perform

William Blair upgraded Diplomat Pharmacy (NYSE:DPLO) to “market perform” from “underperform” after UnitedHealth Group’s (NYSE:UNH) OptumRx agreed to acquire Diplomat for $4 a share. Shares of Diplomat were quoted at $3...

December 9, 2019
Markets

HCW starts Puma Biotechnology at buy; PT $15

H.C. Wainwright launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “buy” rating and $15 price target. The stock closed at $7.44 on Dec. 5. Puma has a marketed drug called Nerlynx, which was approved by the FDA...

December 6, 2019
ADMA Biologics
Markets

Dawson James removes PT for ADMA Biologics

Dawson James Securities removed its prior $4 price target for ADMA Biologics (NASDAQ:ADMA) after the company reported third quarter financial results. The stock was changing hands at $4.09 in afternoon trading on Dec. 5...

December 5, 2019
Check Cap
Markets

Dawson James starts Check Cap at buy; PT $4

Dawson James Securities initiated coverage of Check Cap (NASDAQ:CHEK) with a “buy” rating and $4 price target. The stock closed at $1.39 on Dec. 4. The company has developed an imaging technology’ known as C-Scan, using...

December 5, 2019
Axsome Therapeutics
Markets

BTIG ups Axsome Therapeutics PT to $48 from $25

BTIG raised its price target for Axsome Therapeutics (NASDAQ:AXSM) to $48 from $25 after the company announced positive Phase 2 data for its AXS-12 drug candidate for the treatment of cataplexy and excessive daytime...

December 4, 2019
STAAR Surgical
Markets

BTIG starts STAAR Surgical at buy: PT $46

BTIG initiated coverage of STAAR Surgical (NASDAQ:STAA) with a “buy” rating and $46 price target. The stock closed at $36.82 on Dec. 3. “We believe STAAR owns a superior refractive surgery option to the current standard...

December 4, 2019

Subscribe

Sign up to our weekly BioTuesdays newsletter.